Notice of Investor Presentation

Notice of Investor Presentation

LONDON and PHILADELPHIA - October 23, 2025 - Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, announces the team will present the published data of the platform innovation, the pre|CISION® dual payload peptide drug conjugate (PDC) delivery system, following their return from the 2025 AACR-NCI-EORTC International Molecular Targets Congress.

Christina Coughlin, Chief Executive Officer, David Liebowitz, Chief Medical Officer, Francis Wilson, VP Chemistry and Ruairidh Edwards, Translational Scientist will deliver a presentation via Investor Meet Company at 16:00 BST on Wednesday October 29, 2025.

The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC here.

Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via the Investor Meet Company dashboard up until October 28 09:00 BST, or at any time during the recorded presentation.

-Ends-

For further information from Avacta, please contact:

About Avacta - www.avacta.com

Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION®. The pre|CISION® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.

About pre|CISION®

The key aspect of pre|CISION® is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.